ArticleFrontiers in medicine2026
Prognostic value and immunological significance of t-cell proliferation regulators in pancreatic cancer: a novel predictive model.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is characterized by a highly immunosuppressive microenvironment, limiting the efficacy of immunotherapy. T-cell regulation plays a pivotal role in anti-tumor immunity. However, the prognostic value and therapeutic implications of T-cell regulation-related genes (TRGs) in PC remain largely unexplored. This study aims to construct a TRG-based risk model and validate key therapeutic targets. Methods: Transcriptomic profiles and clinical data were retrieved from TCGA and GEO databases. Non-negative Matrix Factorization (NMF) clustering was performed to identify molecular subtypes. A prognostic risk signature was constructed using LASSO regression analysis. The immune landscape was evaluated via ssGSEA, CIBERSORT and TIDE algorithms. A nomogram was established to predict overall survival, and drug sensitivity was assessed based on IC50 estimation. Crucially, the expression of the key signature gene IL1RN was validated in clinical tissues using qRT-PCR, Western Blot, and immunohistochemistry (IHC). Its function in T-cell mediated cytotoxicity was further verified using co-culture assays. Results: Two distinct molecular subtypes were identified, with Cluster 1 exhibiting an immune-hot phenotype and superior survival. A robust risk model was constructed and validated, serving as an independent prognostic factor. High-risk patients were characterized by an immune-excluded phenotype but showed higher sensitivity to chemotherapeutic agents like Gemcitabine. Experimental validation confirmed that IL1RN was significantly upregulated in PC tissues. Functionally, knockdown of IL1RN significantly enhanced the cytotoxicity of T cells against pancreatic cancer cells Conclusion: We constructed a novel TRG-based prognostic signature that can serve as an auxiliary tool for clinical prognostic evaluation in pancreatic cancer. Furthermore, we validated IL1RN as a critical mechanism of immune resistance. IL1RN is expected to become a novel target for pancreatic cancer immunotherapy, providing experimental evidence for the stratified treatment of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.